格隆汇8月12日丨荣昌生物(09995.HK)公布，公司将于2025年8月22日召开董事会会议，以（其中包括） 审议及通过集团截至2025年6月30日止六个月的中期业绩及其发布。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 RemeGen Co., Ltd.* 榮 昌 生 物 製 藥（ 煙 台 ）股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：9995） 董事會召開日期 榮昌生物製藥（煙台）股份有限公司（「本公司」）之董事會（「董事會」）謹此宣佈， 本公司將於2025年8月22日（星期五）舉行董事會會議，藉以（其中包括）考慮及批 准本公司及其附屬公司截至2025年6月30日止六個月之中期業績及其刊發。 承董事會命 榮昌生物製藥（煙台）股份有限公司 董事長兼執行董事 王威東先生 中華人民共和國，煙台 2025年8月12日 於本公告日期，董事會成員包括執行董事王威東先生、房健民博士、林健先生及 溫慶凱先生；非執行董事王荔強博士及蘇曉迪博士；及獨立非執行董事郝先經先 生、陳雲金先生及黃國濱先生。 * 僅供識別 ...

Group 1 - Beijing Beida Pharmaceutical's subsidiary, Beijing Beida Medicine, has suspended its main business since June 2025 due to the termination of a long-term service contract with Peking University International Hospital [1] - The termination reflects the subsidiary's weak business structure and inability to diversify its client base, which may lead to operational sustainability issues and potential personnel adjustments [1] - The parent company may experience short-term performance impacts as a result of this development [1] Group 2 - Huaxi Biological's fermentation-derived chondroitin sodium has successfully completed the main document registration with the National Medical Products Administration, marking it as the first compliant fermentation-derived chondroitin sodium in China [2] - This new pharmaceutical-grade raw material can be applied in Class II and III medical devices, potentially expanding the company's raw material business applications and serving as a new growth point for performance [2] - Future market expansion and downstream customer integration will be critical for the commercial success of this product [2] Group 3 - Tongrentang announced a change in leadership, with the resignation of Chairman Di Shubing and the election of Zhang Zhaohua as the new chairman [3] - This leadership change is part of normal internal rotation and may indicate a strategic management strengthening and business development push for the company [3] Group 4 - *ST Wuzhong has initiated arbitration against Regen Biotech, Inc. for breach of contract, with the Shenzhen International Arbitration Court accepting the case [4] - The arbitration seeks to confirm the validity of the exclusive agency agreement and may involve a preliminary claim for damages amounting to RMB 1.6 billion, covering various losses [4] - The outcome of this arbitration could significantly impact *ST Wuzhong's operational pressure and stock price, depending on the ruling [4] Group 5 - Rongchang Bio's RC148 has been proposed for inclusion in the breakthrough therapy designation program for treating advanced or metastatic non-small cell lung cancer [5] - This PD-1/VEGF dual antibody is the fourth of its kind to receive such designation, following competitors like Kangfang Biotech and Promis [5] - The competitive landscape for multi-target dual antibodies is intensifying, and Rongchang's progress may further drive technological advancements in the industry [5]

智通财经获悉，君实生物(01877)、荣昌生物(09995)午后齐涨。截至发稿，君实生物涨4.53%，报30.48 港元；荣昌生物(09995)涨1.55%，报65.7港元。 据悉，这是特瑞普利单抗在中国内地递交的第十三项适应症上市申请。该申请主要基于RC48-C016研 究，该研究是一项多中心、随机、开放、阳性药对照的Ⅲ期临床研究，主要研究终点无进展生存期 (PFS)和总生存期(OS)均达到方案预设的优效边界。 本文源自：智通财经网 消息面上，近日，君实生物宣布，国家药品监督管理局已于近日受理公司自主研发的抗PD-1单抗药物 特瑞普利单抗合荣昌生物(09995)自主研发的抗体偶联(ADC)药物维迪西妥单抗用于HER2表达的局部晚 期或转移性尿路上皮癌患者的新适应症上市申请获得受理。 ...

Core Insights - RemeGen Co., Ltd. has received clearance from the FDA for its IND application for phase II clinical trials of its bispecific antibody RC148 in the US [1][2] - RC148 targets PD-1 and VEGF and is developed using RemeGen's bispecific antibody technology platform [2] - The FDA clearance is a significant milestone that is expected to expedite the global development process of RC148 [2] Company Developments - RemeGen is currently conducting clinical trials of RC148 as both a monotherapy and in combination therapy for advanced solid tumors in China [2] - The successful IND application clearance marks an important step in RemeGen's strategy to expand its presence in the global oncology market [1][2]

Core Viewpoint - The domestic innovative drug sector has shifted from a previous upward trend to a phase of volatility, with market participants showing a tendency to buy more as prices drop, indicating a potential long-term investment interest despite short-term fluctuations [1][2]. Group 1: Market Trends - From June 16 to June 25, medical-themed ETFs saw a net inflow of over 6.4 billion yuan, with several leading innovative drug ETFs attracting more than 1.5 billion yuan [1][2]. - The Hong Kong innovative drug index experienced a significant drop of 8.51% from June 16 to June 20, yet funds continued to flow into innovative drug ETFs during this period [2]. - The recent performance of innovative drug stocks has been influenced by the high valuations already priced in, leading to increased sensitivity to any negative news [3][4]. Group 2: Business Development (BD) Impact - On June 26, the announcement from Rongchang Biopharmaceuticals regarding a licensing deal with Vor Bio led to a sharp decline in its stock price, with A-shares dropping over 18% and H-shares over 11% [3][4]. - The market's reaction to the BD announcement was notably negative, attributed to the lower-than-expected upfront payment and the nature of the partner company, which lacks commercialized products [4]. - Analysts suggest that the current market dynamics reflect a disconnect between actual BD outcomes and optimistic market expectations, contributing to volatility in the sector [4][5]. Group 3: Investment Considerations - The innovative drug sector's high volatility necessitates a longer-term investment perspective, as short-term trading strategies may not yield favorable returns [5][6]. - Companies with robust competitive positions and comprehensive business logic are viewed as more favorable investment targets amidst the current market conditions [5][6]. - The potential for significant market value remains in overseas markets, particularly in Europe and the U.S., despite short-term fluctuations in the domestic market [6].

Core Insights - The latest net value of Zhongyin Innovation Medical Mixed A (007718) is 2.1723 yuan, reflecting a decline of 3.54%. The fund has shown a one-month return of 12.66%, a six-month return of 78.76%, and a year-to-date return of 80.53% [1]. Fund Performance - The fund ranks 684 out of 4457 in the one-month category, 23 out of 4316 in the six-month category, and 29 out of 4287 in the year-to-date category [1]. Holdings Overview - The top ten stock holdings of Zhongyin Innovation Medical Mixed A account for a total of 62.83%, with significant positions in companies such as: - Innovent Biologics (8.33%) - Kelun-Biotech (8.15%) - Heng Rui Medicine (8.08%) - CanSino Biologics (8.07%) - New Horizon Health (6.13%) - Bai Li Tianheng (5.99%) - BeiGene (5.97%) - Hansoh Pharmaceutical (4.15%) - Rongchang Biologics (4.05%) - CanSino Biologics-B (3.91%) [1]. Fund Manager Background - Zheng Ning, the fund manager, has a master's degree and has previously held positions at Taikang Asset Management and Zhonggeng Fund Management. He joined Zhongyin Fund Management in 2022 and has been managing the Zhongyin Innovation Medical Mixed Fund since July 1, 2022 [2].

Core Viewpoint - The company Rongchang Biopharma has confirmed its ownership of warrants for 320 million shares of Vor Biopharma Inc., valued at $80 million, with an exercise price of $0.0001 per share, which have not yet been exercised [1] Group 1 - The company holds warrants for 320 million shares of Vor Biopharma Inc. valued at $80 million [1] - The exercise price for the warrants is set at $0.0001 per share [1] - The warrants have not yet been exercised, and further updates will be provided through official announcements [1]

致：香港交易及結算所有限公司 公司名稱: 榮昌生物製藥（煙台）股份有限公司 呈交日期: 2025年8月6日 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 I. 法定/註冊股本變動 截至月份: 2025年7月31日 狀態: 新提交 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09995 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 208,581,239 | RMB | | 1 RMB | | 208,581,239 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 208,581,239 | RMB | | 1 RMB | | 208,581,239 | | 2. 股份分類 | 普通股 | 股份類別 | A | ...

Market Overview - US stock indices rebounded, influenced positively by Trump's market support, leading to a 0.68% rise in Hong Kong stocks [1] - San Francisco Fed President Daly indicated that the timing for interest rate cuts is approaching, with expectations for two 25 basis point cuts this year [1] - Goldman Sachs predicts three consecutive 25 basis point cuts starting in September, with a potential 50 basis point cut if unemployment rises further [1] Domestic Market Sentiment - A-share new account openings in July reached 1.96 million, a 71% year-on-year increase, indicating rising domestic confidence [2] - The stock of Upwind New Materials surged 20% after resuming trading, reigniting market enthusiasm [2] - The steel sector saw a significant rise, with Maanshan Iron & Steel's stock increasing over 15% due to improved loss forecasts and supportive policies [2] Industry Trends - The paper industry is experiencing a price increase, with major companies like Nine Dragons Paper and Lee & Man Paper announcing price hikes [2] - The eleventh batch of centralized drug procurement in China saw a record 45 companies applying for the same drug, intensifying competition in the generic drug market [3] - Investment is shifting towards innovative drugs, with companies like Junshi Biosciences seeing stock increases of nearly 34% due to promising clinical trials [3] Financial Support for Key Industries - A joint guideline from the central bank and seven departments aims to support financing for key manufacturing sectors, including integrated circuits and medical equipment [4] - AI-related companies like Longi Green Energy and Lenovo's server business are seeing stock increases due to new orders and market interest [4] Gaming Industry Performance - The domestic gaming market is projected to reach RMB 168 billion in sales by the first half of 2025, a 14.08% year-on-year increase [4] - Heartbeat Games anticipates a revenue increase of approximately 37% for the first half of 2025, driven by strong performance from self-developed games [4] Individual Company Highlights - Tencent's mobile game "Valorant: Source Action" is set to launch on August 19, with projected annual revenue exceeding RMB 6 billion [5] - Oriental Selection's stock surged nearly 17% ahead of its upcoming financial report, reflecting strong market performance [6] - The Macau gaming sector is experiencing a positive trend, with Morgan Stanley raising its revenue growth forecast for the year from 5% to 10% [6] Technological Advancements - Apple's breakthrough in brain-computer interface (BCI) technology allows users to control devices through thought, indicating a significant market opportunity [7] - The Chinese BCI market is expected to exceed RMB 3.8 billion by 2025, with a CAGR of approximately 20% [7] Investment Opportunities - Kelun-Bio has become a top holding in a major fund, indicating strong market confidence in its innovative drug pipeline [8] - The company has established multiple technology platforms and is expected to accelerate commercialization in 2025 [8]